Previous 10 | Next 10 |
Appointment of industry leader brings broad R&D Oncology Experience to Board TEL AVIV, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor i...
On September 9th, Kitov Pharma ( KTOV ) presented proof-of-concept data displaying NT-219’s mechanism of action in reversing cancer drug resistance in pre-clinical models. NT-219 is a “first-in-class small molecule bi-specific inhibitor” of STAT3 and IRS1/2. Previously, ...
Data validates NT-219 mechanism of action in reversing resistance to various FDA-approved treatments in pancreatic tumor models of mice implanted with biopsies from patients (PDX) NT-219’s novel mechanism of action may open new avenues for combination therapies with targ...
TEL AVIV, Israel, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that Isaac Israel, CEO, and Gil Efron, Depu...
Noteworthy events during the week of September 1 - 9 for healthcare investors. More news on: Synlogic, Inc., Orchard Therapeutics plc, Zosano Pharma Corporation, Healthcare stocks news, , Read more ...
TEL AVIV, Israel, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that Kitov’s subsidiary, TyrN...
- Orbimed, Pontifax and Arkin Holdings to deposit $3.5 million investment in Kitov in escrow - Progress facilitates the advance of activities in development of the oncology asset CM-24 TEL AVIV, Israel, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitovȁ...
Israeli Investigation of Kitov and certain officers has been terminated TEL AVIV, Israel, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion ...
Kitov Pharma (NASDAQ: KTOV ): 1H GAAP EPS of -$0.14. More news on: Kitov Pharma Ltd, Earnings news and commentary, Healthcare stocks news, , Read more ...
TEL AVIV, Israel, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced financial results for the six-month period end...
News, Short Squeeze, Breakout and More Instantly...
Kitov Pharma Ltd. Company Name:
KTOV Stock Symbol:
NASDAQ Market:
REHOVOT, Israel, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that the Purple Biotech manageme...
Virtual Bell-Ringing Ceremony in Celebration of Company’s Recent Name Change to Purple Biotech REHOVOT, Israel, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class thera...
New Name Reflects Company’s Evolution to Advancing First-in-Class Oncology Therapies TEL AVIV, Israel, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (the “Company”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to o...